These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24263002)

  • 41. Functional characteristics of N8, a new recombinant FVIII.
    Christiansen ML; Balling KW; Persson E; Hilden I; Bagger-Sørensen A; Sørensen BB; Viuff D; Segel S; Klausen NK; Ezban M; Lethagen S; Steenstrup TD; Kjalke M
    Haemophilia; 2010 Nov; 16(6):878-87. PubMed ID: 20546031
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An in vitro pharmacodynamic spiking study of befovacimab, a tissue factor pathway inhibitor monoclonal antibody, in blood samples from patients with severe FVIII deficiency.
    Martin EJ; Nolte ME; Kuhn J; Schmidt N; Pfaff N; Brophy DF
    Haemophilia; 2021 Jul; 27(4):690-698. PubMed ID: 33915599
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hemostatic effect of tranexamic acid combined with factor VIII concentrate in prophylactic setting in severe hemophilia A: A preclinical study.
    Janbain M; Enjolras N; Bordet JC; Bolbos R; Brevet M; Leissinger C; Dargaud Y
    J Thromb Haemost; 2020 Mar; 18(3):584-592. PubMed ID: 31782901
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients.
    Bakhtiari K; Kamphuisen PW; Mancuso ME; Hamulyak K; Schutgens RE; Santagostino E; Meijers JC
    Br J Haematol; 2013 Sep; 162(6):827-35. PubMed ID: 23889493
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X.
    Yada K; Nogami K; Wakabayashi H; Fay PJ; Shima M
    Thromb Haemost; 2013 Jun; 109(6):1007-15. PubMed ID: 23467620
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Deletion of tissue factor pathway inhibitor isoform beta or gamma, but not alpha, improves clotting in hemophilic mice.
    Eldem I; Antunes-Heck L; Subramanian R; Lasky NM; Ashworth K; Di Paola J; Girard TJ
    J Thromb Haemost; 2024 Oct; 22(10):2681-2691. PubMed ID: 38925489
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Thrombin generation assay: a useful routine check-up tool in the management of patients with haemophilia?
    Salvagno GL; Astermark J; Lippi G; Ekman M; Franchini M; Guidi GC; Berntorp E
    Haemophilia; 2009 Jan; 15(1):290-6. PubMed ID: 19149855
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acquired hemophilia in the patient suffering from rheumatoid arthritis: case report.
    Drobiecki A; Pasiarski M; Hus I; Sokołowska B; Wątek M
    Blood Coagul Fibrinolysis; 2013 Dec; 24(8):874-80. PubMed ID: 24042266
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C).
    Shima M; Matsumoto T; Fukuda K; Kubota Y; Tanaka I; Nishiya K; Giles AR; Yoshioka A
    Thromb Haemost; 2002 Mar; 87(3):436-41. PubMed ID: 11916076
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma.
    Szlam F; Taketomi T; Sheppard CA; Kempton CL; Levy JH; Tanaka KA
    Anesth Analg; 2008 Mar; 106(3):719-24, table of contents. PubMed ID: 18292408
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Issues complicating precision dosing for factor VIII prophylaxis.
    Valentino LA; Turecek PL; Gritsch H; Butenas S; Mann KG
    Transfus Apher Sci; 2018 Aug; 57(4):472-479. PubMed ID: 30139569
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factor VIII contributes to platelet-fibrin thrombus formation via thrombin generation under low shear conditions.
    Sugita C; Yamashita A; Moriguchi-Goto S; Furukoji E; Takahashi M; Harada A; Soeda T; Kitazawa T; Hattori K; Tamura S; Asada Y
    Thromb Res; 2009 Nov; 124(5):601-7. PubMed ID: 19660789
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Update on factor (F) VIII structure and function-related hemostatic coagulation and its regulatory mechanism (s)].
    Nogami K
    Rinsho Ketsueki; 2021; 62(7):781-789. PubMed ID: 34349063
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Validation of a procedure for potency assessing of a high purity factor VIII concentrate--comparison of different factor VIII coagulant assays and effect of prediluent.
    Mazurier C; Parquet-Gernez A; Goudemand M
    Thromb Haemost; 1990 Oct; 64(2):251-5. PubMed ID: 2125374
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A.
    Matsumoto T; Nogami K; Ogiwara K; Shima M
    Int J Hematol; 2009 Dec; 90(5):576-582. PubMed ID: 19937483
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tissue factor pathway inhibitor: then and now.
    Ellery PE; Adams MJ
    Semin Thromb Hemost; 2014 Nov; 40(8):881-6. PubMed ID: 25377319
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MG1113, a specific anti-tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia.
    Kwak H; Lee S; Jo S; Kwon YE; Kang H; Choi G; Jung ME; Kwak MJ; Kim S; Oh BH; Kim DS; Hwang SH
    Res Pract Thromb Haemost; 2020 Nov; 4(8):1301-1312. PubMed ID: 33313469
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of factor VIII deficiencies and replacement and bypass therapies on thrombus formation under venous flow conditions in microfluidic and computational models.
    Onasoga-Jarvis AA; Leiderman K; Fogelson AL; Wang M; Manco-Johnson MJ; Di Paola JA; Neeves KB
    PLoS One; 2013; 8(11):e78732. PubMed ID: 24236042
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia.
    Maroney SA; Cooley BC; Ferrel JP; Bonesho CE; Nielsen LV; Johansen PB; Hermit MB; Petersen LC; Mast AE
    Proc Natl Acad Sci U S A; 2012 Mar; 109(10):3927-31. PubMed ID: 22355108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.